Comparison of two vasopressor protocols for preventing hypotension post-spinal anesthesia during cesarean section: a randomized controlled trial

For many women undergoing elective cesarean section, spinal anesthesia is the preferred choice for pain relief—it’s effective, fast-acting, and avoids the risks of general anesthesia. But one common, concerning side effect looms: post-spinal anesthesia hypotension. This sudden drop in blood pressure can cause nausea, vomiting, or even fetal distress, affecting up to 80% of women without preventive treatment. Now, a new randomized controlled trial from Chinese researchers compares two drugs to prevent this complication, offering key insights into safer, more comfortable deliveries.

Led by Qian-Qian Fan, Yong-Hui Wang, and colleagues from Xijing Hospital (Fourth Military Medical University, Xi’an) and affiliated institutions, the study evaluates norepinephrine infusion (a continuous low-dose drug) versus ephedrine bolus (a single dose)—two common vasopressors (drugs that raise blood pressure)—to see which better protects mothers and babies.

Why This Matters: The Problem with Post-Spinal Hypotension

Spinal anesthesia works by numbing nerves in the lower back, but it also relaxes blood vessels, reducing blood pressure. For pregnant women, this is riskier: the growing uterus presses on the inferior vena cava, further lowering blood flow to the heart and baby. Ephedrine, a long-used vasopressor, has downsides—it crosses the placenta easily (potentially causing fetal tachycardia), acts slowly, and makes blood pressure hard to adjust. Norepinephrine, a newer option, acts faster and has milder effects on heart rate, making it a promising alternative.

How the Study Worked

The trial enrolled 190 women scheduled for elective cesarean section under spinal anesthesia. Participants were randomly assigned to two groups in a double-blind design (neither patients nor care teams knew who received which drug):

Norepinephrine group (88 women): A continuous infusion of norepinephrine (0.05 µg·kg⁻¹·min⁻¹) starting just before spinal anesthesia and lasting 30 minutes. A 5 mg norepinephrine rescue dose was given if hypotension occurred.
Ephedrine group (89 women): A single 0.15 mg/kg ephedrine bolus right after spinal anesthesia, plus a saline infusion matching the norepinephrine group’s rate. A 5 mg ephedrine rescue dose was used for hypotension.

Hypotension was defined as two consecutive systolic blood pressure (SBP) readings below 90 mmHg or a 20% drop from baseline. Researchers tracked:

Primary outcome: Hypotension within 30 minutes of spinal anesthesia.
Secondary outcomes: Maternal side effects (tachycardia, nausea, dizziness) and neonatal health (Apgar scores, umbilical cord blood gases, and cerebral oxygen saturation [crSO₂] in the first 10 minutes after birth).

Key Results: Norepinephrine Is Safer for Mothers, May Benefit Babies

After excluding dropouts (e.g., failed spinal punctures), 177 women completed the study. The results favored the norepinephrine group across critical measures:

1. Less Hypotension

Only 29.5% of women in the norepinephrine group developed hypotension, compared to 44.9% in the ephedrine group. This means norepinephrine reduced the risk of hypotension by 49% (odds ratio [OR] 0.51, 95% confidence interval [CI] 0.28–0.95).

2. Fewer Heart Problems

Tachycardia (fast heart rate)—a common, uncomfortable side effect of ephedrine—was far less frequent in the norepinephrine group: 52.3% vs. 83.1% (OR 0.22, 95% CI 0.11–0.44).

3. Less Nausea and Vomiting

Just 8% of women in the norepinephrine group experienced nausea or vomiting, compared to 23.6% in the ephedrine group (OR 0.28, 95% CI 0.11–0.70). This is a big win—nausea during surgery is distressing and can delay recovery.

4. Neonatal Benefits (Even Without Short-Term Differences)

Babies in both groups had similar Apgar scores (a measure of health at 1 and 5 minutes after birth) and umbilical cord blood gases (a marker of fetal acidosis, or too much acid in the blood). But there was one crucial difference: cerebral oxygen saturation (crSO₂). Using a non-invasive near-infrared spectroscopy (NIRS) device, researchers found that babies in the norepinephrine group had higher crSO₂ levels in the first 10 minutes after birth (mean difference 2.0%, 95% CI 0.55%–3.45%).

Why does this matter? The newborn brain is extremely sensitive to low oxygen. Higher crSO₂ suggests better cerebral oxygenation, which may reduce the risk of brain injury—even if there are no immediate signs of distress.

Why Norepinephrine Beats Ephedrine

Ephedrine’s flaws are well-known: it crosses the placenta easily (risking fetal tachycardia), has a slow onset, and makes blood pressure hard to titrate (adjust). Norepinephrine, a potent alpha-adrenergic agonist with mild beta-adrenergic effects, acts faster and stabilizes blood pressure more consistently. The continuous infusion also avoids the “spikes and dips” of a single bolus dose, which may explain the lower nausea rates.

The study’s findings align with recent research: a 2018 Anesth Analg study found that prophylactic norepinephrine infusion reduced hypotension during cesarean section more effectively than bolus doses.

Limitations and Future Research

The study isn’t perfect. Researchers didn’t measure cardiac output (the amount of blood the heart pumps), which could explain why norepinephrine improved neonatal crSO₂—better cardiac output means more oxygen to the baby. Also, crSO₂ monitoring started 2 minutes after birth (instead of immediately) due to practical steps like clamping the umbilical cord. Still, data from 2–10 minutes (when crSO₂ changes rapidly) are valuable.

Future research should explore:

Long-term neurodevelopmental outcomes of higher neonatal crSO₂.
How cardiac output affects norepinephrine’s benefits.
Optimal norepinephrine doses for different patient groups (e.g., obese women).

What This Means for You

For women undergoing elective cesarean section, this study suggests that norepinephrine infusion is a safer, more effective option to prevent post-spinal hypotension than ephedrine bolus. It reduces uncomfortable side effects (tachycardia, nausea) and may protect your baby’s brain.

For doctors, the results support a shift toward continuous norepinephrine infusion for hypotension prevention. The dose used (0.05 µg·kg⁻¹·min⁻¹) is safe and effective, making it a practical choice for clinical practice.

The Bottom Line

This randomized controlled trial adds strong evidence that norepinephrine infusion is superior to ephedrine bolus for preventing post-spinal hypotension during cesarean section. It keeps mothers more comfortable and may give babies a healthier start—all while maintaining the safety of spinal anesthesia.

The study was registered on ClinicalTrials.gov (NCT02542748) and published in the Chinese Medical Journal (2021;134(7):792–799). The full study is available at doi.org/10.1097/CM9.0000000000001404.

Was this helpful?

0 / 0